Glutathione Dosing & Reconstitution Guide

Glutathione is typically administered via subcutaneous injection, with a recommended frequency of once daily. Research studies indicate a dose range of 100 to 200 mg per injection, which aligns with findings from various preclinical models exploring its effects on oxidative stress and cellular health. The dosing cycle often consists of 8 weeks of administration followed by a 4-week break, allowing for potential biological recovery and assessment of treatment effects. Morning administration on an empty stomach is frequently preferred, as it may enhance absorption and bioavailability, although individual responses can vary.

For laboratory use, Glutathione is typically provided in a 600 mg vial. To achieve a concentration of 300 mg/mL, it is recommended to reconstitute the powder with 2 mL of sterile water. This concentration facilitates precise dosing for research applications. Proper reconstitution techniques are essential to ensure the integrity of the peptide and its bioactivity. Researchers should consider the stability of the reconstituted solution and adhere to storage recommendations post-reconstitution to maintain compound efficacy.

Studies have employed various titration schedules to assess the optimal dosing of Glutathione. A common approach involves starting with 100 mg once daily during the initial two weeks, followed by an increase to 150 mg daily in weeks three and four. After this initial period, a dose of 200 mg once daily is typically administered from week five onward. This gradual titration allows for monitoring of individual tolerability and response, which is crucial in research settings where variability in biological response can influence outcomes.

The storage conditions for Glutathione are critical for preserving its stability and activity. In its lyophilized form, it can be stored at room temperature, shielded from light, for up to 24 months. Once reconstituted, however, the peptide should be refrigerated at temperatures between 2-8 °C and is recommended for use within 14 days to mitigate degradation. These guidelines are essential for researchers to follow to ensure the reliability of experimental results.

Common injection sites for Glutathione administration include the abdomen and outer thigh. These areas are typically chosen for their accessibility and potential for effective absorption. Research suggests that proper site rotation may help minimize local irritation and enhance the overall comfort of administration. Understanding the anatomical considerations of injection sites can aid in optimizing the delivery of Glutathione for experimental purposes.

Glutathione is generally well tolerated in research settings, with mild side effects reported, such as transient discomfort at the injection site and flushing following intravenous administration. More serious reactions are rare but may include nausea, abdominal cramping, and bloating. Notably, known contraindications include hypersensitivity to Glutathione and asthma, as inhaled forms may provoke bronchospasm. Caution is advised in patients undergoing chemotherapy, as Glutathione may interfere with the efficacy of certain chemotherapeutic agents. Awareness of these safety considerations is crucial for researchers utilizing this compound.